TWiST and U TOX represent utilities applied to time spent in TWiST and TOX health states, respectively. U TWiST was considered 1.00, i.e., the best possible quality of life for patients. U TOX was calculated using EQ-5D index scores from the PRIMA trial. Restricted mean QA-PFS was calculated from the area under the quality-survival product function up to the last PFS of patients randomized to niraparib. Results: Maximum PFS was 27.8 months with niraparib. There were improvements in mean

more »

... for niraparib vs. placebo in the intention-to-treat (ITT) and homologous recombination deficient (HRd) cohorts, with mean (95% confidence interval [CI]) gains of 3.5 (1.7-5.6) and 5.9 (3.5-8.6) months, respectively. Similarly, QA-PFS was significantly longer with niraparib vs. placebo, with mean (95% CI) differences of 4.1 (2.2-5.8) and 6.5 (3.9-8.9) in the ITT and HRd cohorts, respectively. Conclusion: In patients with ovarian cancer, first-line niraparib maintenance was associated with significant gains in QA-TWiST and QA-PFS vs. placebo, confirming the benefit of niraparib in the ITT population and HRd cohort.